

# Rafael Fonseca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5237990/publications.pdf>

Version: 2024-02-01

399  
papers

40,144  
citations

1463

107  
h-index

2747

192  
g-index

401  
all docs

401  
docs citations

401  
times ranked

22527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proceedings, 2003, 78, 21-33.	3.0	1,904
2	Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.	27.8	1,288
3	Promiscuous Mutations Activate the Noncanonical NF- $\kappa$ B Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	16.8	941
4	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, The, 2010, 11, 29-37.	10.7	882
5	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell, 2014, 25, 91-101.	16.8	847
6	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	2.2	841
7	Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2006, 24, 431-436.	1.6	802
8	International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 2009, 23, 2210-2221.	7.2	775
9	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 2004, 22, 3751-3757.	1.6	774
10	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New England Journal of Medicine, 2007, 356, 2582-2590.	27.0	740
11	POEMS syndrome: definitions and long-term outcome. Blood, 2003, 101, 2496-2506.	1.4	694
12	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	7.2	664
13	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.9	642
14	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005, 106, 4050-4053.	1.4	604
15	Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 2003, 101, 4569-4575.	1.4	599
16	Clonal competition with alternating dominance in multiple myeloma. Blood, 2012, 120, 1067-1076.	1.4	575
17	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 2011, 118, 4771-4779.	1.4	552
18	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 5347-5356.	1.6	509

#	ARTICLE	IF	CITATIONS
19	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
20	Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4319-4323.	1.6	479
21	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	3.0	440
22	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	3.0	389
23	Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. <i>Blood</i> , 2012, 120, 1060-1066.	1.4	357
24	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. <i>Blood</i> , 2008, 111, 785-789.	1.4	355
25	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. <i>Leukemia</i> , 2009, 23, 1337-1341.	7.2	347
26	Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. <i>Blood</i> , 2012, 119, 4391-4394.	1.4	338
27	Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. <i>Blood</i> , 2005, 106, 2837-2840.	1.4	337
28	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. <i>Cancer Cell</i> , 2008, 13, 167-180.	16.8	322
29	Clinical Course of Patients With Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2004, 79, 867-874.	3.0	319
30	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002, 100, 1417-1424.	1.4	317
31	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. <i>Leukemia</i> , 2007, 21, 2035-2042.	7.2	317
32	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. <i>Lancet</i> , The, 2010, 375, 1721-1728.	13.7	313
33	Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. <i>Blood</i> , 2002, 99, 3735-3741.	1.4	308
34	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004, 104, 1881-1887.	1.4	300
35	Genetic aberrations and survival in plasma cell leukemia. <i>Leukemia</i> , 2008, 22, 1044-1052.	7.2	299
36	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.	7.2	294

#	ARTICLE	IF	CITATIONS
37	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	3.5	292
38	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5008-5014.	1.6	286
39	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
40	The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. <i>Blood</i> , 2003, 102, 2562-2567.	1.4	257
41	Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. <i>Leukemia</i> , 2011, 25, 1026-1035.	7.2	239
42	Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. <i>Cancer Research</i> , 2007, 67, 2982-2989.	0.9	236
43	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. <i>Blood</i> , 2004, 103, 3960-3963.	1.4	226
44	Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1047-1053.	3.0	221
45	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. <i>Leukemia</i> , 2014, 28, 1725-1735.	7.2	221
46	Thalidomide as initial therapy for early-stage myeloma. <i>Leukemia</i> , 2003, 17, 775-779.	7.2	219
47	Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. <i>Clinical Cancer Research</i> , 2002, 8, 2210-6.	7.0	219
48	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012, 119, 2100-2105.	1.4	218
49	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020, 1, 493-506.	13.2	209
50	Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. <i>Leukemia</i> , 2003, 17, 427-436.	7.2	208
51	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. <i>Blood</i> , 2012, 120, 2280-2289.	1.4	208
52	Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). <i>Blood</i> , 2003, 101, 3801-3807.	1.4	207
53	Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. <i>Cancer Cell</i> , 2005, 7, 39-49.	16.8	202
54	Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. <i>Blood</i> , 2002, 100, 2996-3001.	1.4	199

#	ARTICLE	IF	CITATIONS
55	Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. <i>Leukemia</i> , 2006, 20, 2034-2040.	7.2	195
56	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. <i>Blood</i> , 2015, 125, 443-448.	1.4	195
57	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. <i>Leukemia</i> , 2013, 27, 1738-1744.	7.2	194
58	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. <i>Blood</i> , 2011, 118, 2970-2975.	1.4	193
59	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. <i>Leukemia</i> , 2007, 21, 529-534.	7.2	191
60	Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. <i>Cancer</i> , 2004, 101, 2593-2598.	4.1	190
61	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10%549 patients from the International Myeloma Working Group. <i>Blood</i> , 2008, 111, 4039-4047.	1.4	190
62	Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. <i>Blood</i> , 2014, 124, 536-545.	1.4	190
63	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). <i>Leukemia</i> , 2010, 24, 1934-1939.	7.2	182
64	Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 115, 3416-3417.	1.4	179
65	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	7.2	174
66	Thalidomide in the Treatment of Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2000, 75, 897-901.	3.0	173
67	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. <i>Clinical Cancer Research</i> , 2015, 21, 3986-3994.	7.0	172
68	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review. <i>American Journal of Hematology</i> , 1998, 59, 161-167.	4.1	169
69	Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. <i>Blood</i> , 2006, 108, 2755-2763.	1.4	166
70	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. <i>Blood</i> , 2004, 103, 3271-3277.	1.4	163
71	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	1.6	161
72	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007, 82, 323-341.	3.0	155

#	ARTICLE	IF	CITATIONS
73	Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival. <i>Journal of Clinical Oncology</i> , 2001, 19, 3350-3356.	1.6	154
74	Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor- $\kappa$ B Signaling Pathways in Waldenström's Macroglobulinemia. <i>Cancer Research</i> , 2009, 69, 3579-3588.	0.9	154
75	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3196-3203.	1.6	152
76	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. <i>Mayo Clinic Proceedings</i> , 2010, 85, 824-833.	3.0	152
77	Thalidomide for previously untreated indolent or smoldering multiple myeloma. <i>Leukemia</i> , 2001, 15, 1274-1276.	7.2	151
78	Clinical and biological significance of RAS mutations in multiple myeloma. <i>Leukemia</i> , 2008, 22, 2280-2284.	7.2	150
79	Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. <i>Cancer Research</i> , 2002, 62, 715-20.	0.9	150
80	Testicular lymphoma is associated with a high incidence of extranodal recurrence. <i>Cancer</i> , 2000, 88, 154-161.	4.1	147
81	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. <i>Blood</i> , 2012, 119, 5397-5404.	1.4	144
82	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007, 82, 323-341.	3.0	143
83	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1179-1184.	3.0	142
84	Expression of VEGF and its receptors by myeloma cells. <i>Leukemia</i> , 2003, 17, 2025-2031.	7.2	140
85	Clinical significance of TP53 mutation in myeloma. <i>Leukemia</i> , 2007, 21, 582-584.	7.2	140
86	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	1.6	140
87	Waldenström macroglobulinaemia. <i>Lancet Oncology</i> , The, 2003, 4, 679-685.	10.7	138
88	Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. <i>Blood</i> , 2001, 98, 2266-2268.	1.4	135
89	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	30.7	133
90	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2009, 114, 518-521.	1.4	130

#	ARTICLE	IF	CITATIONS
91	Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. <i>Leukemia</i> , 2006, 20, 807-813.	7.2	129
92	Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. <i>Blood</i> , 2004, 104, 40-42.	1.4	128
93	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2006, 133, 158-164.	2.5	128
94	Identification of genes modulated in multiple myeloma using genetically identical twin samples. <i>Blood</i> , 2004, 103, 1799-1806.	1.4	127
95	Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 257-261.	3.0	126
96	Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. <i>Leukemia</i> , 2001, 15, 981-986.	7.2	123
97	Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling. <i>Journal of Clinical Oncology</i> , 2005, 23, 6339-6344.	1.6	123
98	Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2003, 78, 34-39.	3.0	122
99	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. <i>Blood</i> , 2010, 115, 1343-1350.	1.4	119
100	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012, 119, 4860-4867.	1.4	119
101	Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. <i>Leukemia</i> , 2008, 22, 1282-1284.	7.2	118
102	Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. <i>Blood</i> , 2005, 106, 3553-3558.	1.4	117
103	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002, 100, 1417-24.	1.4	117
104	A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. <i>Blood</i> , 2005, 106, 2156-2161.	1.4	115
105	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	3.0	115
106	The (11;14)(q13;q32) Translocation in Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2000, 113, 831-837.	0.7	111
107	The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. <i>Blood</i> , 2008, 111, 1603-1609.	1.4	111
108	Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. <i>Journal of Clinical Oncology</i> , 2005, 23, 5668-5674.	1.6	110

#	ARTICLE	IF	CITATIONS
109	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
110	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	7.1	110
111	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007, 136, 80-86.	2.5	109
112	Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2007, 138, 700-720.	2.5	109
113	Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. <i>Blood</i> , 2002, 99, 2627-2627.	1.4	107
114	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	3.0	106
115	Prognostic value of angiogenesis in solitary bone plasmacytoma. <i>Blood</i> , 2003, 101, 1715-1717.	1.4	105
116	6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 150-153.	1.0	105
117	Waldenström's Macroglobulinemia. <i>Oncologist</i> , 2000, 5, 63-67.	3.7	104
118	Targeting TMPRSS2 in SARS-CoV-2 Infection. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1989-1999.	3.0	100
119	Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. <i>Blood</i> , 2010, 115, 1594-1604.	1.4	95
120	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.	2.5	95
121	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. <i>Haematologica</i> , 2009, 94, 380-386.	3.5	94
122	Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma. <i>Cancer Genetics and Cytogenetics</i> , 1999, 113, 73-77.	1.0	91
123	Clinical implication of centrosome amplification in plasma cell neoplasm. <i>Blood</i> , 2006, 107, 3669-3675.	1.4	90
124	The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2001, 98, 1271-1272.	1.4	89
125	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. <i>Leukemia</i> , 2004, 18, 624-627.	7.2	88
126	The clinical significance of cereblon expression in multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 23-28.	0.8	84



#	ARTICLE	IF	CITATIONS
127	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. <i>Bone Marrow Transplantation</i> , 2004, 34, 161-167.	2.4	82
128	Plasma cell leukemia. <i>Blood Reviews</i> , 2011, 25, 107-112.	5.7	81
129	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	2.4	81
130	Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. <i>Blood</i> , 2015, 126, 1294-1301.	1.4	80
131	Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. <i>Blood</i> , 2007, 109, 1228-1232.	1.4	78
132	Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem cell transplantation and review of the literature. <i>American Journal of Hematology</i> , 2005, 78, 288-294.	4.1	71
133	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. <i>British Journal of Haematology</i> , 1998, 101, 296-301.	2.5	70
134	Smoldering multiple myeloma requiring treatment: time for a new definition?. <i>Blood</i> , 2013, 122, 4172-4181.	1.4	70
135	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. <i>Blood</i> , 2003, 101, 827-830.	1.4	69
136	Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDAC) alone (95-80-53) or 2-CDAC and rituximab (N0189) in the North Central Cancer Treatment Group. <i>Cancer</i> , 2008, 113, 108-116.	4.1	68
137	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. <i>Modern Pathology</i> , 2012, 25, 651-660.	5.5	66
138	Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 24-29.	2.5	65
139	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1551-1551.	1.6	64
140	Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. <i>Blood</i> , 2008, 112, 1931-1941.	1.4	64
141	Chromosome 1q21 abnormalities in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 83.	6.2	64
142	Anemia After Orchiectomy. <i>American Journal of Hematology</i> , 1998, 59, 230-233.	4.1	62
143	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. <i>Bone Marrow Transplantation</i> , 2004, 34, 235-239.	2.4	62
144	Treatment With Bortezomib of a Patient Having Hyper IgG4 Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 217-219.	0.4	62

#	ARTICLE	IF	CITATIONS
145	Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. PLoS ONE, 2012, 7, e43192.	2.5	62
146	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. American Journal of Hematology, 2001, 68, 269-275.	4.1	61
147	DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors. Cancer Research, 2010, 70, 6934-6944.	0.9	61
148	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 42-43.	1.4	58
149	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	4.1	57
150	A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.. Blood, 2007, 110, 74-74.	1.4	57
151	Proteomic Analysis of Waldenstrom Macroglobulinemia. Cancer Research, 2007, 67, 3777-3784.	0.9	56
152	Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genetics and Cytogenetics, 2002, 132, 55-60.	1.0	55
153	IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia, 2006, 20, 174-176.	7.2	55
154	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Mayo Clinic Proceedings, 2010, 85, 532-537.	3.0	55
155	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54
156	Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood, 2013, 121, 3147-3152.	1.4	53
157	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10.	6.2	53
158	An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma. PLoS ONE, 2012, 7, e44997.	2.5	53
159	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	2.4	52
160	Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood, 2005, 105, 794-803.	1.4	52
161	Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood, 2009, 113, 635-645.	1.4	52
162	Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens. Clinical Cancer Research, 2011, 17, 4245-4253.	7.0	52

#	ARTICLE	IF	CITATIONS
163	Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. <i>Journal of Clinical Investigation</i> , 2008, 118, 1750-64.	8.2	52
164	Lessons from next-generation sequencing analysis in hematological malignancies. <i>Blood Cancer Journal</i> , 2013, 3, e127-e127.	6.2	50
165	Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. <i>Haematologica</i> , 2013, 98, 1586-1592.	3.5	50
166	Chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 1998, 103, 704-710.	2.5	49
167	Cerebral Toxicity in Patients Treated for Small Cell Carcinoma of the Lung. <i>Mayo Clinic Proceedings</i> , 1999, 74, 461-465.	3.0	49
168	Clarithromycin (Biaxin)â€lowâ€dose dexamethasone (BiRd) versus lenalidomideâ€lowâ€dose dexamethasone (Rd) for newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2010, 85, 664-669.	4.1	49
169	Bone marrow angiogenesis in multiple myeloma: effect of therapy. <i>British Journal of Haematology</i> , 2002, 119, 665-671.	2.5	48
170	t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. <i>Blood</i> , 2012, 120, 3949-3957.	1.4	48
171	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2012, 156, 326-333.	2.5	48
172	A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.. <i>Blood</i> , 2006, 108, 799-799.	1.4	48
173	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 492-498.	1.4	47
174	A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. <i>Leukemia</i> , 2005, 19, 118-125.	7.2	46
175	Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. <i>Leukemia</i> , 2012, 26, 1698-1701.	7.2	46
176	Content Development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): Use of Qualitative and Quantitative Methods for Scale Construction. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 1094-1104.	1.2	45
177	Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. <i>Leukemia</i> , 2010, 24, 1406-1411.	7.2	44
178	A phase II trial of imatinib in patients with refractory/relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 39-42.	1.3	43
179	Targeted sequencing using a 47 gene multiple myeloma mutation panel (M <sup>&gt;3</sup> P) in â€17p high risk disease. <i>British Journal of Haematology</i> , 2015, 168, 507-510.	2.5	42
180	Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 1087.	2.6	42

#	ARTICLE	IF	CITATIONS
181	Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. <i>Leukemia</i> , 2010, 24, 833-842.	7.2	41
182	A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e66361.	2.5	41
183	Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 563-565.	2.5	41
184	Prognostic Factors and Staging in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1115-1140.	2.2	40
185	Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1. <i>Blood</i> , 2011, 117, e190-e197.	1.4	40
186	Thrombosis in multiple myeloma (MM). <i>Hematology</i> , 2012, 17, s177-s180.	1.5	40
187	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2011, 118, 4359-4362.	1.4	39
188	Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1111-1120.	2.8	37
189	Plasma cell leukemia. <i>Current Treatment Options in Oncology</i> , 2001, 2, 205-216.	3.0	36
190	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	6.2	36
191	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 161-168.	1.0	35
192	Molecular pathogenesis of Waldenstrom's macroglobulinemia. <i>Haematologica</i> , 2012, 97, 1281-1290.	3.5	35
193	Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: A case report. , 1997, 55, 148-155.		34
194	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. <i>Leukemia</i> , 2010, 24, 1498-1505.	7.2	34
195	Staging and prognostication of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 21-31.	2.2	33
196	Multiple myeloma cells' capacity to decompose H <sub>2</sub> O <sub>2</sub> determines lenalidomide sensitivity. <i>Blood</i> , 2017, 129, 991-1007.	1.4	33
197	High-Resolution Genomic Analysis in Waldenström's Macroglobulinemia Identifies Disease-Specific and Common Abnormalities with Marginal Zone Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 39-42.	1.4	32
198	Monoclonal Gammopathy of Undetermined Significance Does Not Affect Outcomes in Patients Undergoing Solid Organ Transplants. <i>Transplantation</i> , 2011, 92, 570-574.	1.0	32

#	ARTICLE	IF	CITATIONS
199	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32
200	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 35, 599-605.	1.3	31
201	Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. <i>British Journal of Haematology</i> , 2003, 123, 305-308.	2.5	31
202	Ploidy status rarely changes in myeloma patients at disease progression. <i>Leukemia Research</i> , 2006, 30, 266-271.	0.8	31
203	Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. <i>Leukemia</i> , 2008, 22, 459-461.	7.2	31
204	Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. <i>Leukemia</i> , 2013, 27, 925-931.	7.2	31
205	Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival. <i>Blood</i> , 2006, 108, 798-798.	1.4	31
206	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	6.2	30
207	Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. <i>British Journal of Haematology</i> , 2011, 155, 340-348.	2.5	29
208	Natural history of thromboembolism in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 31-36.	3.0	28
209	Comparison of Twin and Autologous Transplants for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1118-1124.	2.0	28
210	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.4	28
211	Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. <i>British Journal of Haematology</i> , 2001, 112, 975-980.	2.5	27
212	Genetics and cytogenetics of Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 142-145.	2.2	27
213	Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 431-438.	6.1	27
214	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 239-247.	2.0	27
215	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e340-e349.	4.6	27
216	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. <i>Annals of Hematology</i> , 2018, 97, 1453-1462.	1.8	26

#	ARTICLE	IF	CITATIONS
217	Many and multiple myeloma(s). <i>Leukemia</i> , 2003, 17, 1943-1944.	7.2	25
218	Analysis of Somatic Hypermutation and Antigenic Selection in the Clonal B Cell in Immunoglobulin Light Chain Amyloidosis (AL). <i>Journal of Clinical Immunology</i> , 2004, 24, 340-353.	3.8	24
219	Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 802-810.	4.1	24
220	Myeloma: Classification and Risk Assessment. <i>Seminars in Oncology</i> , 2013, 40, 554-566.	2.2	24
221	Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. <i>Patient Education and Counseling</i> , 2019, 102, 1602-1612.	2.2	24
222	PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. <i>Oncotarget</i> , 2016, 7, 61806-61819.	1.8	23
223	CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1169-1180.	2.2	22
224	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	1.4	21
225	Direct to Drug screening as a precision medicine tool in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 54.	6.2	20
226	DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription. <i>PLoS ONE</i> , 2012, 7, e52626.	2.5	20
227	High-Throughput Genomic Analysis in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 106-108.	0.4	19
228	Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. <i>Leukemia</i> , 2007, 21, 2358-2359.	7.2	18
229	MicroRNA expression in tumor cells from Waldenström's macroglobulinemia reflects both their normal and malignant cell counterparts. <i>Blood Cancer Journal</i> , 2011, 1, e24-e24.	6.2	18
230	Genomic Abnormalities of Waldenström Macroglobulinemia and Related Low-Grade B-Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 198-201.	0.4	18
231	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	6.2	18
232	A novel report of cigaFISH and cytogenetics in POEMS syndrome. <i>American Journal of Hematology</i> , 2008, 83, 840-841.	4.1	17
233	Effect of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practice Certified Tissue Banking Facility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 666-673.	2.5	17
234	Review of molecular diagnostics in multiple myeloma. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 453-459.	3.1	16

#	ARTICLE	IF	CITATIONS
235	Extramedullary Cardiac Multiple Myeloma – A Case Report and Contemporary Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 246-252.	0.4	16
236	Burden of disease progression in patients with multiple myeloma in the US. <i>Leukemia and Lymphoma</i> , 2020, 61, 47-55.	1.3	16
237	Combination Therapy with CC-5013 (Lenalidomide; Revlimid <sup>®</sup> , <sup>c</sup> ) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004, 104, 331-331.	1.4	16
238	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	1.4	16
239	Expression and mutation status of candidate kinases in multiple myeloma. <i>Leukemia</i> , 2007, 21, 1124-1127.	7.2	15
240	Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 284-290.e5.	0.4	15
241	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR <sup>®</sup> CD) for untreated low <sup>®</sup> grade non <sup>®</sup> Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	4.1	15
242	Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 642.	6.2	15
243	Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. <i>Transplantation</i> , 2018, 102, 1994-2001.	1.0	15
244	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 995-1002.	5.2	15
245	t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. <i>British Journal of Haematology</i> , 2003, 120, 170-171.	2.5	14
246	Centrosomes and myeloma; Aneuploidy and proliferation. <i>Environmental and Molecular Mutagenesis</i> , 2009, 50, 697-707.	2.2	14
247	Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements. <i>PLoS ONE</i> , 2014, 9, e87113.	2.5	14
248	Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. <i>Thrombosis Research</i> , 2014, 133, 606-609.	1.7	14
249	Genetics of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 525-536.	1.7	13
250	Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 315-317.	1.4	12
251	Erdheim Chester Disease treated successfully with cladribine. <i>Respiratory Medicine Case Reports</i> , 2016, 18, 37-40.	0.4	12
252	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post <sup>®</sup> autologous stem cell transplantation lenalidomide maintenance therapy. <i>American Journal of Hematology</i> , 2021, 96, E157-E162.	4.1	12

#	ARTICLE	IF	CITATIONS
253	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. <i>Leukemia and Lymphoma</i> , 2000, 39, 391-395.	1.3	11
254	Strategies for Risk-Adapted Therapy in Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 304-310.	2.5	11
255	Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. <i>Leukemia</i> , 2012, 26, 1671-1674.	7.2	11
256	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. <i>Blood</i> , 2012, 120, 194-194.	1.4	11
257	Practical Aspects in the Diagnosis and Management of Aplastic Anemia. <i>American Journal of the Medical Sciences</i> , 1997, 313, 159-169.	1.1	11
258	Genomics in multiple myeloma: biology and clinical implications. <i>Pharmacogenomics</i> , 2005, 6, 563-573.	1.3	10
259	Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. <i>Value in Health</i> , 2020, 23, 441-450.	0.3	9
260	Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).. <i>Blood</i> , 2006, 108, 3527-3527.	1.4	9
261	Laboratory correlates in multiple myeloma: how useful for prognosis?. <i>Blood Reviews</i> , 2001, 15, 97-102.	5.7	8
262	Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia. <i>Current Opinion in Hematology</i> , 2007, 14, 369-374.	2.5	8
263	The MYDas touch of next-gen sequencing. <i>Blood</i> , 2013, 121, 2373-2374.	1.4	8
264	Phase II Trial of Lenalidomide (Revlimid <sup>®</sup> ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma. <i>Blood</i> , 2008, 112, 91-91.	1.4	8
265	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 486-492.e1.	0.4	7
266	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. <i>Blood</i> , 2007, 110, 190-190.	1.4	7
267	Establishment and Characterization of an Ig Lambda Secreting Cell Line from a Patient with AL Amyloidosis.. <i>Blood</i> , 2006, 108, 3520-3520.	1.4	7
268	Approach to a patient with cardiac amyloidosis. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 567-574.	0.2	7
269	Risk Stratification of Patients with Newly Diagnosed Multiple Myeloma: Optimizing Treatment Based on Pretreatment Characteristics. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 200-207.	1.4	6
270	A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans. <i>Journal of Cancer Education</i> , 2012, 27, 294-298.	1.3	6



#	ARTICLE	IF	CITATIONS
271	Phase II trial of nabâ€paclitaxel in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2016, 91, E504-E505.	4.1	6
272	Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 364-370.	3.8	6
273	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.. Blood, 2004, 104, 129-129.	1.4	6
274	High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.. Blood, 2006, 108, 3514-3514.	1.4	6
275	Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	6
276	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	6
277	Transfusion-Dependent Anemia After Initiation of Androgen Deprivation Therapy for Metastatic Prostate Cancer. Urology, 2007, 70, 811.e5-811.e8.	1.0	5
278	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€2. Mayo Clinic Proceedings, 2010, 85, 197-199.	3.0	5
279	Dissecting Karyotypic Patterns in Non-Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 552-558.	0.4	5
280	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 621-630.	0.4	5
281	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. Blood, 2005, 106, 781-781.	1.4	5
282	Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).. Blood, 2008, 112, 1740-1740.	1.4	5
283	Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,. Blood, 2011, 118, 4184-4184.	1.4	5
284	Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, e194-e197.	1.6	4
285	The Importance of Economic Trade-offs in Cancer Drug Pricing. Mayo Clinic Proceedings, 2018, 93, 976-979.	3.0	4
286	Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. Leukemia, 2020, 34, 3060-3063.	7.2	4
287	A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).. Blood, 2005, 106, 2546-2546.	1.4	4
288	A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.. Blood, 2007, 110, 3601-3601.	1.4	4

#	ARTICLE	IF	CITATIONS
289	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years. <i>Blood</i> , 2011, 118, 3963-3963.	1.4	4
290	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. <i>Blood</i> , 2017, 130, 864-864.	1.4	4
291	Do $\hat{t}2$ microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?. <i>Leukemia</i> , 2008, 22, 1080-1081.	7.2	3
292	How Physicians Interpret Research Funding Disclosures. <i>New England Journal of Medicine</i> , 2012, 367, 2358-2360.	27.0	3
293	Frontline treatment of multiple myeloma. <i>Hematology</i> , 2012, 17, s101-s104.	1.5	3
294	Association of Clinical Researchers and Educators A Statement on Relationships Between Physicians and Industry. <i>Endocrine Practice</i> , 2012, 18, 1029-1037.	2.1	3
295	Recurrent Chromosome Abnormalities Define Nonoverlapping Unique Subgroups of Tumors in Patients With Chronic Lymphocytic Leukemia and Known Karyotypic Abnormalities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 467-476.	0.4	3
296	CGH Protocols: Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2013, 973, 87-98.	0.9	3
297	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e727-e734.	1.9	3
298	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2009, 114, 2868-2868.	1.4	3
299	The Case of the Phantom Bladder. <i>Journal of Urology</i> , 1997, 157, 1354-1354.	0.4	2
300	Author reply. <i>Cancer</i> , 2000, 89, 714-714.	4.1	2
301	Cell lines of hyperdiploid myeloma, are we there yet?. <i>British Journal of Haematology</i> , 2008, 140, 579-580.	2.5	2
302	Innovation in myeloma treatments PARP excellence!. <i>Blood</i> , 2011, 118, 6234-6235.	1.4	2
303	Antibodies Create Killer Bonds in Myeloma. <i>Cancer Cell</i> , 2017, 31, 305-307.	16.8	2
304	Diagnosis and Staging of Multiple Myeloma and Related Disorders. <i>Hematologic Malignancies</i> , 2018, , 17-28.	0.2	2
305	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <i>Anti-Cancer Drugs</i> , 2019, 30, 859-865.	1.4	2
306	Management of multiple myeloma during COVID-19 pandemic. <i>Leukemia Research Reports</i> , 2020, 14, 100212.	0.4	2

#	ARTICLE	IF	CITATIONS
307	Characterization of Frontline Treatment Patterns and Attrition Rates According to Subsequent Lines of Therapy in Non-Transplant Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3291-3291.	1.4	2
308	Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3479-3479.	1.4	2
309	Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.. <i>Blood</i> , 2005, 106, 508-508.	1.4	2
310	Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1171-1171.	1.4	2
311	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011, 118, 2942-2942.	1.4	2
312	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. <i>Blood</i> , 2013, 122, 3174-3174.	1.4	2
313	Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.. <i>Blood</i> , 2004, 104, 3649-3649.	1.4	2
314	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	1.4	2
315	Assays for Neoplastic Cell Enrichment in Bone Marrow Samples. , 2003, 85, 333-342.		1
316	A "not so micro" model for a "macro" problem. <i>Blood</i> , 2005, 106, 1143-1144.	1.4	1
317	Multiple myeloma and FISH (but no CHIPS). <i>Blood</i> , 2007, 109, 3132-3133.	1.4	1
318	DIAGNOSIS AND GENETIC CLASSIFICATION OF MULTIPLE MYELOMA. , 0, , 1-17.		1
319	La genética como factor pronóstico y terapéutico en el mieloma múltiple. <i>Revista Medica De Chile</i> , 2009, 137, .	0.2	1
320	Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S46-S47.	1.4	1
321	Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic. <i>Expert Review of Hematology</i> , 2011, 4, 579-581.	2.2	1
322	Amitriptyline-Induced Agranulocytosis With Bone Marrow Confirmation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e183-e185.	0.4	1
323	Bone Disease in Myeloma: The Claws of CRAB. <i>Clinical Cancer Research</i> , 2016, 22, 1301-1303.	7.0	1
324	Prevalence of BCL-2/(H) Translocation in Healthy African Americans. <i>Annals of Hematology</i> , 2017, 96, 51-55.	1.8	1

#	ARTICLE	IF	CITATIONS
325	Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. <i>Blood Cancer Journal</i> , 2021, 11, 35.	6.2	1
326	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. <i>Blood</i> , 2007, 110, 241-241.	1.4	1
327	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007, 110, 2477-2477.	1.4	1
328	Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.. <i>Blood</i> , 2008, 112, 1663-1663.	1.4	1
329	A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma. <i>Blood</i> , 2011, 118, 1824-1824.	1.4	1
330	Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage. <i>Blood</i> , 2011, 118, 3150-3150.	1.4	1
331	Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients. <i>Blood</i> , 2011, 118, 5070-5070.	1.4	1
332	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2012, 120, 4079-4079.	1.4	1
333	Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas. <i>Blood</i> , 2012, 120, 420-420.	1.4	1
334	The Genomic Landscape Of Primary Central Nervous System Lymphomas. <i>Blood</i> , 2013, 122, 504-504.	1.4	1
335	Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy.. <i>Blood</i> , 2004, 104, 334-334.	1.4	1
336	Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possible Tumorigenic Mechanism in Myeloma.. <i>Blood</i> , 2006, 108, 113-113.	1.4	1
337	Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.. <i>Blood</i> , 2007, 110, 560-560.	1.4	1
338	PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma. <i>Blood</i> , 2012, 120, 1846-1846.	1.4	1
339	Promiscuous Cryptic Rearrangements of the MYC Locus Cis-Dysregulate MYC Expression and Are Present in the Majority of Patients with Hyperdiploid Myeloma. <i>Blood</i> , 2012, 120, 724-724.	1.4	1
340	The Role of the Histone Demethyltransferase Gene JMJD1C and H3K9 Methylation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 3527-3527.	1.4	1
341	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 3771-3771.	1.4	1
342	Financial Hardship Amongst Patients with Hematologic Malignancies: Using the EMR to Streamline and Prioritize Patient-Centered Care. <i>Blood</i> , 2021, 138, 661-661.	1.4	1

#	ARTICLE	IF	CITATIONS
343	Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients. American Journal of Hematology, 2022, 97, E69.	4.1	1
344	Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2020, 136, 33-34.	1.4	1
345	Plasma cell neoplasms. , 0, , 244-265.		0
346	Cytogenetic Abnormalities in MGUS and Myeloma. , 2013, , 589-599.		0
347	Waldenström Macroglobulinemia. , 2004, , 205-225.		0
348	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. Blood, 2004, 104, 1475-1475.	1.4	0
349	Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy.. Blood, 2004, 104, 2446-2446.	1.4	0
350	Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM).. Blood, 2004, 104, 4299-4299.	1.4	0
351	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy.. Blood, 2004, 104, 787-787.	1.4	0
352	The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.. Blood, 2004, 104, 3461-3461.	1.4	0
353	Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.. Blood, 2004, 104, 4852-4852.	1.4	0
354	Sequencing the Multiple Myeloma Kinome: Absence of Mutation in Known Malignancy-Associated Kinases.. Blood, 2004, 104, 783-783.	1.4	0
355	Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma.. Blood, 2005, 106, 5102-5102.	1.4	0
356	Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab.. Blood, 2005, 106, 5178-5178.	1.4	0
357	Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma.. Blood, 2005, 106, 5109-5109.	1.4	0
358	Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells.. Blood, 2005, 106, 1555-1555.	1.4	0
359	Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia.. Blood, 2005, 106, 3267-3267.	1.4	0
360	High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.. Blood, 2006, 108, 2093-2093.	1.4	0

#	ARTICLE	IF	CITATIONS
361	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	1.4	0
362	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	1.4	0
363	Genomic-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.. Blood, 2007, 110, 396-396.	1.4	0
364	Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor.. Blood, 2007, 110, 1476-1476.	1.4	0
365	Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.. Blood, 2007, 110, 2491-2491.	1.4	0
366	Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis.. Blood, 2007, 110, 2490-2490.	1.4	0
367	The Multiple Myeloma Research Consortium Genomics Initiative.. Blood, 2007, 110, 2498-2498.	1.4	0
368	Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).. Blood, 2007, 110, 2471-2471.	1.4	0
369	Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics. , 2008, , 57-76.		0
370	Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications.. Blood, 2008, 112, 1677-1677.	1.4	0
371	Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CR1K Protein, a Novel Protein Regulating Migration and Adhesion. Blood, 2008, 112, 643-643.	1.4	0
372	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. Blood, 2009, 114, 2877-2877.	1.4	0
373	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	1.4	0
374	MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis.. Blood, 2009, 114, 834-834.	1.4	0
375	CpG Methylation Profiling in Multiple Myeloma.. Blood, 2009, 114, 604-604.	1.4	0
376	Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse. Blood, 2011, 118, 2838-2838.	1.4	0
377	Generation of An Automated Tool for the Identification of Genetics Markers and Signatures in Multiple Myeloma Risk-Stratification. Blood, 2011, 118, 2881-2881.	1.4	0
378	Comprehensive High-Resolution Studies Differentiate and Characterize Hypodiploid Multiple Myeloma. Blood, 2011, 118, 2869-2869.	1.4	0

#	ARTICLE	IF	CITATIONS
379	Comparison of Cytogenetics Between Asian and Caucasian Myeloma Reveal Higher Frequency of Abnormalities Associated with Poor Prognosis in Asian Patients. Blood, 2011, 118, 5060-5060.	1.4	0
380	Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide. Blood, 2011, 118, 127-127.	1.4	0
381	Genomic Strategies Determining Progression from MGUS to Multiple Myeloma. , 2013, , 3-24.		0
382	DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription. Blood, 2012, 120, 1285-1285.	1.4	0
383	Genetics of Multiple Myeloma. , 2013, , 1-16.		0
384	Tissue Factor and Hematological Neoplasias. Blood, 2012, 120, 5132-5132.	1.4	0
385	Molecular Classification and Risk Stratification. , 2014, , 55-64.		0
386	Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors. Blood, 2013, 122, 4434-4434.	1.4	0
387	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2855-2855.	1.4	0
388	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). Blood, 2013, 122, 1854-1854.	1.4	0
389	Calcium Isotopic Composition and Its Association With Multiple Myeloma Disease Activity. Blood, 2013, 122, 3157-3157.	1.4	0
390	Role Of Folate Receptor Targeted Therapy In Multiple Myeloma. Blood, 2013, 122, 4436-4436.	1.4	0
391	Results of a Flow Cytometry Assay Measuring Oxidative Stress Relief As a Predictor of Immunomodulatory Drugs (IMiDs) Sensitivity in Myeloma. Blood, 2018, 132, 4443-4443.	1.4	0
392	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	1.4	0
393	Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide. Blood, 2019, 134, 4410-4410.	1.4	0
394	Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM). Blood, 2021, 138, 2668-2668.	1.4	0
395	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). Blood, 2021, 138, 2285-2285.	1.4	0
396	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0

#	ARTICLE	IF	CITATIONS
397	Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy. <i>Blood</i> , 2020, 136, 43-43.	1.4	0
398	Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 9, 1-16.	0.3	0
399	Assessment of MRD in patients with hematologic malignancies: clinical insights. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 9, 7-10.	0.3	0